2022
Fifth OD dossier development completed
2021
First launch of own-developed (OD) product at patent expiry | Fourth OD dossier development completed | Full commercial structure in place | National acknowledgement of outstanding performance and substantial growth | EUR16.3m funding secured from Icelandic investor community | 130 employees
2020
Leadership structure finalised | Third own-developed (OD) dossier development completed | First submissions of OD product dossiers to European health authorities
2019
Acquisition of R&D operations and facilities from Teva, including 35 expert personnel | First delivery of a contract manufactured product
2018
Coripharma founded | Acquisition of Actavis ehf. in Iceland from Teva, including manufacturing facilities, equipment and quality systems
Powerful heritage
2016
Actavis acquired by Teva Pharmaceuticals, as part of its global acquisition of Allergan’s generics business
2012
Actavis acquired by Watson Pharmaceuticals (later Allergan) and merged entity retains the name Actavis
1998 - 2009
Facility expanded twice, increasing capacity | Delta hf. merges with Icelandic company Pharmaco, then rebranded as Actavis in 2004
1981
Icelandic pharmaceutical company Delta hf. establishes manufacturing facility to focus primarily on domestic production